BiVACOR

“People think it’s the patients who are benefiting most from this technology. They’re not. It’s the family that’s benefiting most.” – Daniel Timms, Founder & CTO of BiVACOR Learn more about our founder's inspiring story and dedicated vision to bring the BiVACOR total artificial heart (TAH) to people in need, as we prepare for our upcoming first-in-human bridge-to-transplant procedures. https://lnkd.in/eAu6F_C3 The Sydney Morning Herald  The Age amanda hooton #HeartFailure #HeartDisease #Cardiology #MedTech #HealthTech #MedicalDevices

“I’m incredibly proud to witness the successful first-in-human implant of our Total Artificial Heart (TAH). This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” - Daniel Timms, Founder & CTO of BiVACOR Good Morning America #heartfailure #heartdisease #cardiology #medtech https://lnkd.in/gnPce5AA

Following the first implantation of the BiVACOR Total Artificial Heart (TAH) implant, on July 17, we are excited to announce that a donor heart became available and was transplanted into the patient. This allowed for the removal of the BiVACOR TAH, meeting a goal of the FDA Early Feasibility Study to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-heart-transplant solution for patients living with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended. Congratulations to the The Texas Heart Institute, BiVACOR, Baylor College of Medicine, St. Luke's Health, and Texas Medical Center teams for this incredible advancement in #cardiovascularhealth. Read the patient update: https://lnkd.in/gQ6rg3Nz

Together with The Texas Heart Institute, Baylor College of Medicine, and Texas Medical Center, we have successfully completed the first-in-human implantation of the BiVACOR Total Artificial Heart as part of the U.S. FDA Early Feasibility Study. 🎙️“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” - Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR 🎙️“The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant. We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.” - Dr. Joseph G. Rogers, M.D., President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research. The successful implantation of BiVACOR’s TAH highlights the potential of innovative technologies to address critical challenges in cardiac care, such as long transplantation waitlists. BiVACOR and The Texas Heart Institute remain committed to advancing the field of cardiac medicine and improving outcomes for patients worldwide. Learn more about today’s announcement in our joint press release: https://lnkd.in/gBTGFqww> William Cohn Alexis Shafii  #HeartFailure #HeartDisease #Cardiology #MedTech

"The BiVACOR TAH is the first device designed to replace an entire heart with a long-term solution. Nobody has done that before." – Daniel Timms, Founder & CTO of BiVACOR In the coming months, our BiVACOR total artificial heart (TAH) will undergo evaluation as a bridge to heart transplant for biventricular heart failure patients. Dive into the Engineers Australia article below to discover how the BiVACOR TAH came to fruition, and visit our website (www.bivacor.com) to learn more! Caroline Riches https://lnkd.in/e5KYrJYi #HeartFailure #HeartDisease #Cardiology #MedTech #HealthTech #MedicalDevices

On this episode of 'Inside the Studio', Joseph G. Rogers, M.D., president & CEO of The Texas Heart Institute, talks with our Chief Medical Officer, Dr. William Cohn, about the potential of the BiVACOR® Total Artificial Heart (TAH) to revolutionize treatment for patients with severe biventricular heart failure. We're proud to partner with The Texas Heart Institute and other leading heart transplant institutions on our upcoming first-in-human Early Feasibility Studies. Learn more at https://bivacor.com/ #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices https://lnkd.in/dsb_xuU8

Watch as our Chief Medical Officer, William Cohn, presented the BiVACOR® Total Artificial Heart (TAH) at The Texas Heart Institute's Cardiology Grand Rounds. We're proud to partner with The Texas Heart Institute and other leading heart transplant institutions on our upcoming first-in-human Early Feasibility Studies.   Our novel TAH uses magnetic levitation (MAGLEV) technology, the same principle used in high-speed trains, the design includes left and right vanes positioned on a common rotor to form the only moving part, a magnetically suspended double-sided centrifugal impeller. Even though there are no valves or flexing ventricle chambers, the pulsatile outflow is made possible by rapidly cycling the rotational speed of the impeller. The non-contact suspension provides large blood gaps minimizing blood trauma and eliminating mechanical wear to offer a durable, reliable, and biocompatible heart replacement.   Learn more at https://bivacor.com/   #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices

On Monday at #THT2024, BiVACOR® founder & CTO Daniel Timms presented our novel Total Artificial Heart (TAH). What is the BiVACOR TAH? 👇 The BiVACOR Total Artificial Heart is designed as the first long-term therapy dedicated to patients with severe biventricular heart failure. It is an implantable total artificial heart based on rotary blood pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of providing enough cardiac output to an adult male undergoing exercise. Using magnetic levitation (MAGLEV) technology, the same principle used in high-speed trains, the design includes left and right vanes positioned on a common rotor to form the only moving part, a magnetically suspended double-sided centrifugal impeller. Even though there are no valves or flexing ventricle chambers, the pulsatile outflow is made possible by rapidly cycling the rotational speed of the impeller. The non-contact suspension provides large blood gaps minimizing blood trauma and eliminating mechanical wear to offer a durable, reliable, and biocompatible heart replacement. View the slides from THT at TCTMD here: https://lnkd.in/e6FAx5bQ Please note that a free registration is required to view. #tht #tht24 #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices

Will you be at THT in Boston March 4 - 6? Daniel Timms, Founder & CTO of BiVACOR®, is presenting the company’s revolutionary Total Artificial Heart (TAH). Daniel’s session occurs during Monday’s Concurrent Session 2: 'LVADs: Pipeline of New Pumps' at 2:50 PM EST, titled ‘BiVACOR: A Novel, Magnetically Levitated Rotary Pump-Based TAH'.  Check back for a link to the recording if you miss it.

A great news article on Daniel Timms, PhD, and the BiVACOR Artificial Heart. https://lnkd.in/etpyuitx